Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
Citations
Citations to this article as recorded by
The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma? Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani Cancers.2022; 14(21): 5352. CrossRef
Hereditary renal cell tumors: Clinicopathologic importance Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro annals of urologic oncology.2021;[Epub] CrossRef
Von Hippel-Lindau Disease: Current Challenges and Future Prospects
Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer OncoTargets and Therapy.2020; Volume 13: 5669. CrossRef
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang Frontiers in Endocrinology.2020;[Epub] CrossRef
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman European Urology.2019; 76(6): 754. CrossRef
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong Frontiers in Oncology.2019;[Epub] CrossRef
A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang Cancer Biology & Therapy.2018; 19(9): 766. CrossRef
Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management Brian Shuch, Jin Zhang Journal of Clinical Oncology.2018; 36(36): 3560. CrossRef
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung Cancer Research and Treatment.2016; 48(1): 409. CrossRef
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka Internal Medicine.2016; 55(6): 629. CrossRef
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R Oncotarget.2016; 7(51): 85306. CrossRef
Pharmacogenomic biomarkers for personalized cancer treatment C. Rodríguez‐Antona, M. Taron Journal of Internal Medicine.2015; 277(2): 201. CrossRef
Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos Journal of Clinical Investigation.2015; 125(5): 1987. CrossRef
Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev EPMA Journal.2015;[Epub] CrossRef